https://orcid.org/0000-0001-6012-9453
Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Marilyn N Bulloch. (2023) Treatment and prevention of influenza in geriatric patients. Expert Review of Clinical Pharmacology 16:9, pages 825-841.
Read now
Read now
Francesco Lapi, Alexander Domnich, Ettore Marconi, Alessandro Rossi & Claudio Cricelli. (2022) Adjuvanted versus non-adjuvanted standard-dose influenza vaccines in preventing all-cause hospitalizations in the elderly: a cohort study with nested case-control analyses over 18 influenza seasons. Expert Review of Vaccines 21:11, pages 1647-1653.
Read now
Read now
Francesco Lapi, Alexander Domnich, Ettore Marconi, Alessandro Rossi, Ignazio Grattagliano, Erik Lagolio, Gerardo Medea, Aurelio Sessa, Iacopo Cricelli, Giancarlo Icardi & Claudio Cricelli. (2022) Predicting the risk of severe COVID-19 outcomes in primary care: development and validation of a vulnerability index for equitable allocation of effective vaccines. Expert Review of Vaccines 21:3, pages 377-384.
Read now
Read now
Asim Biswas, Alok K. Chakrabarti & Shanta Dutta. (2020) Current challenges: from the path of “original antigenic sin” towards the development of universal flu vaccines. International Reviews of Immunology 39:1, pages 21-36.
Read now
Read now
Articles from other publishers (27)
Francesco Lapi, Alexander Domnich, Ettore Marconi, Alessandro Rossi, Ignazio Grattagliano & Claudio Cricelli. (2023)
Examining the effectiveness and duration of adjuvanted
vs
. non‐adjuvanted influenza vaccines in protecting older adults against symptomatic SARS‐CoV‐2 infection
. British Journal of Clinical Pharmacology.
Crossref
Crossref
John D. Grabenstein, Pietro Ferrara, Lorenzo G. Mantovani & Ian McGovern. (2023) Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine. Vaccine 41:49, pages 7409-7418.
Crossref
Crossref
Francesco Lapi, Elisa Bianchini, Ettore Marconi, Gerardo Medea, Carlo Piccinni, Aldo P. Maggioni, Letizia Dondi, Antonella Pedrini, Nello Martini & Claudio Cricelli. (2023) A methodology to assess the population size and estimate the needed resources for new licensed medications by combining clinical and administrative databases: The example of glycated haemoglobin in type 2 diabetes. Pharmacoepidemiology and Drug Safety 32:10, pages 1083-1092.
Crossref
Crossref
Simon de Lusignan, Mansoor Ashraf, Filipa Ferreira, Manasa Tripathy, Ivelina Yonova, Imran Rafi, George Kassianos & Mark Joy. (2023) Impact of General Practitioner Education on Acceptance of an Adjuvanted Seasonal Influenza Vaccine among Older Adults in England. Behavioral Sciences 13:2, pages 130.
Crossref
Crossref
John J. Treanor. 2020. Viral Infections of Humans. Viral Infections of Humans
1
57
.
John J. Treanor. 2020. Viral Infections of Humans. Viral Infections of Humans
1
57
.
Iana H. Haralambieva, Huy Quang Quach, Inna G. Ovsyannikova, Krista M. Goergen, Diane E. Grill, Gregory A. Poland & Richard B. Kennedy. (2022) T Cell Transcriptional Signatures of Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine in Older Adults. Viruses 14:12, pages 2763.
Crossref
Crossref
Sonia Jangra, Gabriel Laghlali, Angela Choi, Raveen Rathnasinghe, Yong Chen, Soner Yildiz, Lynda Coughlan, Adolfo García-Sastre, Bruno G. De Geest & Michael Schotsaert. (2022) RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine. Frontiers in Immunology 13.
Crossref
Crossref
Francesco Lapi, Ettore Marconi, Maria Rosaria Gualano, Davide Liborio Vetrano, Ignazio Grattagliano, Alessandro Rossi & Claudio Cricelli. (2022) A Cohort Study on Influenza Vaccine and All-Cause Mortality in Older Adults: Methodological Concerns and Public Health Implications. Drugs & Aging 39:8, pages 645-656.
Crossref
Crossref
Martina E. McMenamin, Helen S. Bond, Sheena G. Sullivan & Benjamin J. Cowling. (2022) Estimation of Relative Vaccine Effectiveness in Influenza: A Systematic Review of Methodology. Epidemiology 33:3, pages 334-345.
Crossref
Crossref
Mahrukh Imran, Joan Puig-Barbera, Justin R Ortiz, Lauren Fischer, Dan O’Brien, Machaon Bonafede, James A Mansi & Constantina Boikos. (2022) Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season. Open Forum Infectious Diseases 9:5.
Crossref
Crossref
Elisabetta Alti, Fiona Ecarnot, Stefania Maggi, Jean-Pierre Michel, Silvestro Scotti & Tommasa Maio. 2022. The Role of Family Physicians in Older People Care. The Role of Family Physicians in Older People Care
89
105
.
Kevin W McConeghy, H Edward Davidson, David H Canaday, Lisa Han, Elie Saade, Vince Mor & Stefan Gravenstein. (2021) Cluster-randomized Trial of Adjuvanted Versus Nonadjuvanted Trivalent Influenza Vaccine in 823 US Nursing Homes. Clinical Infectious Diseases 73:11, pages e4237-e4243.
Crossref
Crossref
Brenda L. Coleman, Ruth Sanderson, Mendel D. M. Haag & Ian McGovern. (2021) Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis. Influenza and Other Respiratory Viruses 15:6, pages 813-823.
Crossref
Crossref
Constantina Boikos, Lauren Fischer, Dan O’Brien, Joe Vasey, Gregg C Sylvester & James A Mansi. (2021) Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons. Clinical Infectious Diseases 73:5, pages 816-823.
Crossref
Crossref
Lisa A. Grohskopf, Elif Alyanak, Jill M. Ferdinands, Karen R. Broder, Lenee H. Blanton, H. Keipp Talbot & Alicia M. Fry. (2021) Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season. MMWR. Recommendations and Reports 70:5, pages 1-28.
Crossref
Crossref
Marina Amaral de Avila Machado, Cristiano S. Moura, Michal Abrahamowicz, Brian J. Ward, Louise Pilote & Sasha Bernatsky. (2021) Relative effectiveness of influenza vaccines in elderly persons in the United States, 2012/2013-2017/2018 seasons. npj Vaccines 6:1.
Crossref
Crossref
Constantina Boikos, Mahrukh Imran, Van Hung Nguyen, Thierry Ducruet, Gregg C. Sylvester & James A. Mansi. (2021) Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications. Vaccines 9:8, pages 862.
Crossref
Crossref
Stephen I. Pelton, Victoria Divino, Maarten J. Postma, Drishti Shah, Joaquin Mould-Quevedo, Mitch DeKoven & Girishanthy Krishnarajah. (2021) A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018–19 influenza season. Vaccine 39:17, pages 2396-2407.
Crossref
Crossref
William David Strain, James Mansi, Constantina Boikos, Michael Boivin & William A. Fisher. (2021) Achieving Influenza Vaccine Uptake Target in Canada via a Pharmacy-Led Telephone Discussion during the 2019–2020 Season. Vaccines 9:4, pages 312.
Crossref
Crossref
Lisa A. Grohskopf, Elif Alyanak, Karen R. Broder, Lenee H. Blanton, Alicia M. Fry, Daniel B. Jernigan & Robert L. Atmar. (2020) Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season. MMWR. Recommendations and Reports 69:8, pages 1-24.
Crossref
Crossref
Stephen I. Pelton, Victoria Divino, Drishti Shah, Joaquin Mould-Quevedo, Mitch DeKoven, Girishanthy Krishnarajah & Maarten J. Postma. (2020) Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season. Vaccines 8:3, pages 446.
Crossref
Crossref
Hector S Izurieta, Yoganand Chillarige, Jeffrey Kelman, Yuqin Wei, Yun Lu, Wenjie Xu, Michael Lu, Douglas Pratt, Michael Wernecke, Thomas MaCurdy & Richard Forshee. (2020) Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018–2019. The Journal of Infectious Diseases 222:2, pages 278-287.
Crossref
Crossref
Silvia Cocchio, Tolinda Gallo, Stefania Del Zotto, Elena Clagnan, Andrea Iob, Patrizia Furlan, Marco Fonzo, Chiara Bertoncello & Vincenzo Baldo. (2020) Preventing the Risk of Hospitalization for Respiratory Complications of Influenza among the Elderly: Is There a Better Influenza Vaccination Strategy? A Retrospective Population Study. Vaccines 8:3, pages 344.
Crossref
Crossref
Philippe Buchy & Selim Badur. (2020) Who and when to vaccinate against influenza. International Journal of Infectious Diseases 93, pages 375-387.
Crossref
Crossref
Haley L. Dugan, Carole Henry & Patrick C. Wilson. (2020) Aging and influenza vaccine-induced immunity. Cellular Immunology 348, pages 103998.
Crossref
Crossref
Lisa A. Grohskopf, Elif Alyanak, Karen R. Broder, Emmanuel B. Walter, Alicia M. Fry & Daniel B. Jernigan. (2019) Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season. MMWR. Recommendations and Reports 68:3, pages 1-21.
Crossref
Crossref